JSSH(000518)2014-08-07 16:00Financial Performance - The company achieved operating revenue of CNY 131,805,467.14, representing a year-on-year increase of 22.53%[21]. - The net profit attributable to shareholders reached CNY 22,866,490.75, a significant turnaround from a loss of CNY 1,181,422.06 in the same period last year, marking a growth of 2,035.51%[21]. - The net profit after deducting non-recurring gains and losses was CNY 19,952,947.33, up 865.95% compared to CNY 2,065,629.07 in the previous year[21]. - The company's basic and diluted earnings per share were both CNY 0.0222, a substantial increase of 2,118.18% from a loss of CNY 0.0011 per share last year[21]. - The weighted average return on net assets improved to 3.33%, compared to -0.16% in the previous year[21]. - The company's revenue for the reporting period was ¥131,805,467.14, representing a year-on-year increase of 22.53% compared to ¥107,572,043.03 in the same period last year[31]. - Operating profit amounted to CNY 26,668,075.80, significantly up from CNY 1,977,707.52 in the prior period[112]. - Net profit for the period was CNY 21,245,316.18, recovering from a net loss of CNY 3,947,568.04 in the same period last year[112]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 833,904,219.63, reflecting a 1.38% increase from CNY 822,583,877.99 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 3.39% to CNY 697,977,238.69 from CNY 675,110,747.94 at the end of the previous year[21]. - Total liabilities decreased to CNY 81,880,964.89 from CNY 91,805,939.43, a decline of approximately 10.8%[106]. - Shareholders' equity increased to CNY 752,023,254.74 from CNY 730,777,938.56, reflecting a growth of about 2.9%[106]. - Current assets totaled CNY 444,340,918.16, slightly down from CNY 449,558,189.10, indicating a decrease of about 1.5%[104]. - Non-current assets rose to CNY 389,563,301.47 from CNY 373,025,688.89, representing an increase of approximately 4.4%[105]. Cash Flow - Cash flow from operating activities decreased by 71.05% to ¥7,481,507.63, down from ¥25,843,273.55 year-on-year[31]. - The net cash flow from investing activities improved by 74.71%, with a net outflow of ¥23,045,519.67 compared to ¥91,123,276.97 in the previous year[32]. - The cash outflow from investment activities was 116,455,480.80 RMB, with a net cash flow from investment activities of -23,045,519.67 RMB[119]. - The total cash inflow from operating activities was 4,814,969.61 RMB, significantly lower than 42,715,831.78 RMB in the previous period[122]. - The net increase in cash and cash equivalents was -18,962,952.50 RMB, reflecting a challenging cash flow environment[119]. Expenses - Operating costs increased to ¥54,842,749.19, a rise of 4.20% from ¥52,631,538.28 in the previous year[31]. - Sales expenses surged by 42.57% to ¥16,050,901.04, primarily due to increased promotional and hospitality expenses in Beijing[31]. - Management expenses decreased by 15.55% to ¥33,167,971.67, down from ¥39,276,330.61 year-on-year[31]. - The company reported a significant increase in income tax expenses, which rose by 102.51% to ¥5,424,148.89, attributed to higher profits from Beijing Sihuan[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 167,315[90]. - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 40,000,000 shares, accounting for 3.89% of the total shares[91]. - Jiangyin Deyuan Wool Textile Co., Ltd. conducted a repurchase transaction of 19,630,000 shares, representing 1.91% of the total share capital[92]. - The total number of shares after the recent changes is 1,029,556,222, with 100% being unrestricted shares[88]. - There were no changes in the controlling shareholder or actual controller during the reporting period[93]. Business Strategy and Operations - The company plans to focus on expanding its market share and diversifying its business strategy in the health industry[29]. - The significant increase in revenue from the wholly-owned subsidiary Beijing Sihuan was attributed to increased supply following last year's GMP renovation[29]. - The company operates in the pharmaceutical industry, focusing on the production of injectables and other medications[136]. - The company has been listed on the Shenzhen Stock Exchange since 1993, under the stock code "000518" and the name "Sihuan Bio"[134]. Legal and Compliance - A lawsuit was filed against Xinjiang Aidi for 6 million yuan in construction payments, with the court date yet to be determined[84]. - The company has not engaged in any related party transactions during the reporting period[65][66]. - The company did not distribute cash dividends, issue bonus shares, or increase share capital from capital reserves in the previous year[51]. Research and Development - Research and development investment increased by 6.06% to ¥2,278,412.63, compared to ¥2,148,142.57 in the previous year[31]. - The company has not disclosed any new product developments or market expansion strategies in this report[107]. - The company has not reported any new product launches or technological advancements during this period[112]. Accounting Policies - The financial statements prepared by the company comply with the requirements of the enterprise accounting standards, reflecting a true and complete financial status[139]. - The company recognizes the fair value of identifiable net assets acquired in business combinations, with adjustments made to the current profit and loss if the fair value can be reliably measured[144]. - The company does not adjust the beginning balances of the consolidated balance sheet for subsidiaries acquired through non-same control business combinations[148].